Learning About and Living With Toxicity: A Qualitative Study of Patients Receiving Immune Checkpoint Inhibitors For Melanoma or Lung Cancer and Their Caregivers

Ayo Falade, M. Boulanger, Kelly Hsu, Roshni Sarathy, Riley Fadden, Kerry L. Reynolds, Lara Traeger, Jennifer S. Temel, Joseph A. Greer, Laura A. PetrilloResearch Square 2024 · DOI

Abstract

Patients perceived that ICI toxicity counseling was overwhelming yet were encouraged by oncologists' reassurance that serious side effects were manageable and by the framing of toxicity as a sign of efficacy. We identified opportunities to improve communication of ICI risks and benefits.

Introduction

Immune Checkpoint Inhibitors (ICIs) have transformed the treatment landscape for advanced melanoma and non-small cell lung cancer (NSCLC). By "unleashing" the immune system to target cancer, these therapies also introduce unique immune-related adverse events (irAEs) that can affect various organ systems. While clinical data on these toxicities is abundant, the subjective patient experience—how they learn about, process, and live with these risks—remains under-explored. This study investigates how patients and caregivers navigate the "deluge" of information provided during clinical counseling.

Methods and Participants

Researchers at Massachusetts General Hospital conducted a qualitative study using a framework approach. Data were gathered through semi-structured interviews with 42 patients and 10 caregivers, alongside audio recordings of initial oncology consultations. This dual-method approach allowed for a comparison between retrospective reflections and real-time clinical interactions.

The study cohort was predominantly white and highly educated, with nearly half of the patients holding a college degree or higher.

Demographic characteristics of the study participants, including patients (n=42) and caregivers (n=10).

Key Insights: The Paradox of Information

The "Drug Commercial" Effect

Patients often likened side-effect counseling to the rapid-fire disclaimers in pharmaceutical advertisements. The high volume of information was frequently perceived as "shocking" or "scary," leading to cognitive overload where patients would "phase out" and stop retaining specific details.

Reassurance over Statistics

Specific risk percentages were rarely remembered. Instead, patients prioritized the emotional takeaway: the oncologist's reassurance that the medical team was prepared to manage any side effects that might arise.

Toxicity as a Sign of Efficacy

A significant finding was the psychological reframing of toxicity. Clinicians often described side effects (like a rash) as evidence that the immune system was "revved up" and actively fighting the tumor. This association turned negative physical symptoms into a source of hope, with some patients even wishing for mild side effects as proof of treatment success.

Clinical Context and Outcomes

Most patients proceeded with ICI treatment despite the risks, often feeling they had no viable alternative. Caregivers played a vital role as "external hard drives," recording information and monitoring symptoms that patients might overlook or forget during the stress of a diagnosis.

Clinical characteristics of the patient cohort, including types of ICI and reasons for discontinuation.

Discussion and Future Directions

The study's findings are limited by its single-center design and the demographic homogeneity of the participants, which may not reflect the experiences of patients in community settings or those with lower health literacy.

To improve communication, the authors suggest moving toward "humanistic" learning models. Recommended strategies include:

  • Teach-back methods: Asking patients to explain risks in their own words.
  • Narrative education: Using patient stories to make abstract risks more concrete.
  • Digital decision aids: Providing materials that can be reviewed at home, away from the high-pressure environment of the clinic.

By addressing these communication gaps, clinicians can better support patients and caregivers in managing the complexities of modern immunotherapy.

Summary updated

Abstract

Patients perceived that ICI toxicity counseling was overwhelming yet were encouraged by oncologists' reassurance that serious side effects were manageable and by the framing of toxicity as a sign of efficacy. We identified opportunities to improve communication of ICI risks and benefits.
BibTeX
@inproceedings{falade2024learning,
  author = {Ayo Falade and M. Boulanger and Kelly Hsu and Roshni Sarathy and Riley Fadden and Kerry L. Reynolds and Lara Traeger and Jennifer S. Temel and Joseph A. Greer and Laura A. Petrillo},
  title = {{Learning About and Living With Toxicity: A Qualitative Study of Patients Receiving Immune Checkpoint Inhibitors For Melanoma or Lung Cancer and Their Caregivers}},
  booktitle = {Research Square},
  year = {2024},
  doi = {10.21203/rs.3.rs-4576328/v1},
}
Figure